🧵 ORBITA-CTO Seeing a study like ORBITA-CTO being published — regardless of its results — is a beautiful thing. This level of commitment to producing high-quality, as-unbiased-as-possible evidence in interventional cardiology should be praised. It took 4 years to randomize 50 patients. That's dedication. Think about what this team had to do: Noise-cancelling headphones, deep sedation, clocks removed from every room, scripted handovers, overnight admission for both arms, dual-operator procedures lasting 3+ hours — all to protect the blinding. Bang blinding index ≈ 0. It worked. Design: 50 patients, single-vessel CTO, confirmed ischemia + viability, J-CTO ≤3, no bystander disease. 1:1 to CTO PCI or placebo after dual-injection angiography. All anti-anginals stopped at randomization. Daily symptom tracking via ORBITA-app for 6 months. Patient-initiated re-titration only. Primary endpoint: angina symptom score (Bayesian ordinal MOST model, daily repeated measures). CTO PCI vs placebo: OR 4.38 (95% CrI 1.57–12.69) Pr(Benefit) = 0.996 Driven by angina frequency: OR 4.38 (95% CrI 1.55–11.78) Pr(Benefit) = 0.997 In patient-centered terms: CTO PCI yielded ~31 additional angina-free days over 6 months vs placebo. 95% CrI: 11.1–50.7 Pr(Benefit) > 0.999 That's roughly 5 extra angina-free days per month. SAQ domains were consistent: Angina frequency: +10.7 (CrI 1.4–20.2) Physical limitation: +13.5 (CrI 4.5–22.3) Quality of life: +18.2 (CrI 5.4–30.5) Summary score: +13.7 (CrI 4.2–23.2) All Pr(Benefit) ≥ 0.988. CCS class also improved. Dyspnea and EQ-5D did not separate. Procedural quality was outstanding: 96% technical success, 92% IVUS-guided, experienced dual-operator teams. One failed PCI case — averaging 6 angina episodes/day — was included in ITT. This biased against the PCI arm. But the treatment effect survived it. Why does this matter so much? EuroCTO (Werner et al.) showed CTO PCI improved symptoms vs OMT at 1 year, sustained at 3 years. But it was open-label, with 17.5% crossover from OMT to PCI. Without blinding, the placebo contribution to symptom relief was unknown. ORBITA-CTO quantified it. Both arms improved — so yes, the placebo response was substantial. But the PCI effect was immediate and sustained. The placebo group progressively needed more anti-anginals. Now, what ORBITA-CTO does NOT prove: 1. Benefit in multivessel disease or high-complexity CTOs (J-CTO 4–5) 2. Prognostic benefit (not designed for hard endpoints) 3. Generalizability beyond expert centers with 96% success rates 4. Benefit on dyspnea or generic quality of life I know. N=50 is small. Credible intervals are wide. This was an expert-center study with carefully selected lesions. Noted. But 8,631 follow-up days of daily symptom data, a Bayesian framework designed for this exact scenario, and verified blinding give it far more inferential weight than sample size alone suggests. For years, CTO PCI skeptics had a legitimate point: no blinded evidence. That point is now addressed. CTO PCI relieves angina beyond placebo — in well-selected patients, at experienced centers. Agreed. Hats off to the ORBITA-CTO team for doing this the hard way. Our field is better for it. And by the way, this is not me celebrating the results. I don't do CTO. But it makes me happy to see good medical science being made. #ORBITACTO #CardiologyX #InterventionalCardiology #ACC26 @JACCJournals